Quick answer: Jōto Transmission, a French search fund led by Pierre-Philippe de Bouville in partnership with Cassius Search’s Stanislas Simon-Beaulieu, completed the acquisition of myDiabby Healthcare on September 22, 2026. Terms were not disclosed. myDiabby is a Class IIa reimbursed diabetes remote-monitoring platform used by more than 200,000 patients and 10,000+ healthcare professionals a year in France.
Deal
Jōto Transmission (Pierre-Philippe de Bouville) → myDiabby Healthcare
- Price
- Undisclosed
- Status
- Closed · Sep 22, 2026
- Sector
- Digital health / diabetes remote monitoring · France
myDiabby Healthcare is a Class IIa reimbursed medical device platform for remote diabetes monitoring, used by more than 200,000 patients and 10,000+ healthcare professionals annually in France.
- Search partner: Cassius Search (Stanislas Simon-Beaulieu)
- Backed by: Bpifrance, French family offices and entrepreneurs, Aurica Search Fund, EPA Investissements
Who is Jōto Transmission?
Jōto Transmission is a search fund led by entrepreneur Pierre-Philippe de Bouville, run in partnership with Cassius Search’s Stanislas Simon-Beaulieu — a dual-searcher structure where two individuals share the search and, eventually, operating responsibilities rather than a single solo searcher. The fund was capitalized specifically to find and acquire one business to run directly, financed by a syndicate of French family offices, entrepreneurs, and institutional search-fund investors including Bpifrance (France’s public investment bank), Aurica Search Fund, and EPA Investissements.
Why a digital health platform
myDiabby fit the search-fund model well: a software-and-device platform with reimbursed, recurring revenue rather than a labor-intensive services model.
The Class IIa medical device classification is also significant: reaching that regulatory status, and the reimbursement approval that typically follows it in the French healthcare system, is a multi-year process that creates a real barrier to entry. A buyer acquiring an already-approved, already-reimbursed platform serving 200,000+ patients a year is buying past that risk entirely — a meaningfully different (and safer) proposition than backing a pre-approval digital health startup.
Buyer Spotlight
Jōto Transmission
Search fund
Healthcare platforms with regulatory approval already secured and reimbursed, recurring revenue already established are a distinct search-fund sub-category from the more common industrial or services targets — worth watching whether more searchers follow this same “buy the already-de-risked healthtech platform” playbook.
WhoBoughtWho tracks acquisitions like these as they’re announced — browse the full acquisition history, explore the private equity and search fund directories, or subscribe to WhoBoughtWho Weekly for verified deals delivered every week.